linjc16/ctgov huggingface dataset:
Robotic Bariatric Database (RBD) Collaborative

Study Overview
=================
Brief Summary
-----------------
With increased prevalence of obesity in the general population over the past 30 years, researchers have been focused on the development of new treatment options to achieve long-lasting weight loss. In 1991, the National Institutes of Health Conference Statement on Gastrointestinal Surgery for Severe Obesity developed a consensus stating that bariatric surgery was the most effective treatment for obesity since it is associated with good long-term results in terms of weight loss, glycemic control and decreased mortality. To collect and store clinical data related to the treatment outcomes of robotic bariatric surgery in order to develop an evidence base such that physicians can provide the best possible care to patients undergoing surgical weight loss interventions.

Detailed Description
-----------------
With increased prevalence of obesity in the general population over the past 30 years, researchers have been focused on the development of new treatment options to achieve long-lasting weight loss.

Official Title
-----------------
Robotic Bariatric Database (RBD) Collaborative

Conditions
-----------------
Weight Loss, Obesity

Intervention / Treatment
-----------------
* Procedure: robotic bariatric surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 years of age Eligible for or have undergone robotic bariatric surgery per the treating physician Undergone robotic bariatric surgery between January 2018 and December 2019 Exclusion Criteria: Do not meet the Study Inclusion Criteria l

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects that have undergone robotic bariatric surgery<br>Subjects that have undergone robotic bariatric surgery between January 2018 and December 2019 | Procedure: robotic bariatric surgery<br>* robotic bariatric surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Date of Birth | mm/dd/yyyy | January 2018- December2019 | 
| Principal Operative Procedure is an Initial Primary Metabolic or Bariatric Procedure | Yes or No | January 2018- December 2019 | 
| Patient has a history of metabolic or bariatric surgery | Yes or No | January 2018- December 2019 |
Pre-extractive Inter-radicular Implant Bed Preparation Versus Conventional Post-extractive Inter-radicular Implant Bed Preparation in Mandibular Molars

Study Overview
=================
Brief Summary
-----------------
Pre-extractive Inter-radicular Implant Bed Preparation versus Conventional Post-extractive Inter-radicular Implant Bed Preparation in Mandibular Molars

Official Title
-----------------
Implant in Mandibular Molars

Conditions
-----------------
Randomized Clinical Trial

Intervention / Treatment
-----------------
* Procedure: Post-extractive inter-radicular implant bed preparation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with badly decayed posterior molar teeth. Distance from height of inter-radicular furcation of mandibular molars to the mandibular canal should be equal to or more than 10 mm Exclusion Criteria: Distance from height of inter-radicular furcation of mandibular molars to the mandibular canal equal to or less than 8 mm. Heavy smokers more than 20 cigarettes per day.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pre-extractive inter-radicular implant bed preparation<br> | Procedure: Post-extractive inter-radicular implant bed preparation<br>* Implant placement in mandibular molars<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implant stability | By ostell in newten scale | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Marginal bone loss | By cone beam xray in millimeters scale | 1 year |
New Vectorcardiogram Analysis a Good Predictor of Coronary Disease in Patients With Normal Rest 12-leads ECG

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine whether a new vectorcardiogram (VCG) analysis will facilitate the detection of significant coronary disease (CAD) in patients with normal rest 12-leads ECG (NE).

Detailed Description
-----------------
Patients with NE will undergo coronary angiography for routine indications. Prior to the angiography a computerized simultaneous multi-leads ECG will be recorded and, using a new dedicated algorithm for 3D electrical activity reconstruction, the investigators will plot the horizontal VCG of the whole ECG cycle. Using this new VCG analysis we will determine whether the patients have normal coronary arteries or coronary disease.

Official Title
-----------------
Spacial Relation of QRS-T Vectocardiogram is a Good Predictor of Coronary Disease in Patients With Normal Rest 12-leads ECG

Conditions
-----------------
Cardiovascular Disease

Intervention / Treatment
-----------------
* Procedure: Routine coronary angiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with normal rest 12-leads ECG Exclusion Criteria: Patients with significant irregular heart beat Patients with heart failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Routine coronary angiography patients<br> | Procedure: Routine coronary angiography<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of CAD in patients undergoing routine coronary angiography | Following angiography patients will be categorized as having normal coronary arteries (NC) or coronary disease (CD) if more than 50% lumen diameter narrowing is found in one of the arteries. | One month |
HR-QoL and Sexuality in Mirena Inserted Contraception Users

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the changes in the quality of life, as well as in the sexual activity, in women inserted with MIRENA, a hormonal contraceptive intra-uterine system, over the first 12 months of use. Patients switching from oral contraception to an intrauterine contraceptive device (here: MIRENA) will be observed in the first year post MIRENA insertion.

Official Title
-----------------
A Multicenter, Open Labelled, Uncontrolled, Phase IV Clinical Study to Evaluate the Health-related Quality of Life and Sexual Well-being in Young (18-35) Healthy Mirena Users Switching From OC, Over the First Year Post-insertion.

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Drug: Mirena


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy woman willing to, or having to switch from her OC to another contraceptive method Exclusion Criteria: - Any contraindication to Mirena insertion/use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Mirena<br>* Mirena 52mg during 1 year<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health-related QoL score |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sexuality Index, treatment satisfaction, usual safety outcomes |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intra-uterine contraception, Intrauterine Devices
Rinitis y Sinusitis según la Gravedad Del Asma

Study Overview
=================
Brief Summary
-----------------
Based on the evidence for the common pathway in asthma presentation, our working hypothesis is that asthma severity and lack of control are related to the prevalence and severity of nasal and sinusal inflammatory pathology, and especially to chronic rhinosinusitis with nasal polyps.

Detailed Description
-----------------
Primary objective: To assess the prevalence and severity of rhinitis and rhinosinusitis, with or without nasal polyposis, in asthmatic patients depending on severity of their disease. Secondary objectives: To assess the impact of nasal and sinusal pathology on asthma control. To correlate asthma severity to rhinitis and rhinosinusitis. To compare the potential association between chronic rhinosinusitis, with and without nasal polyposis, and asthma severity, and to detect radiographic differences, markers of atopy, and pulmonary function.

Official Title
-----------------
PREVALENCIA, GRAVEDAD E IMPACTO DE LA RINITIS Y DE LA SINUSITIS SEGÚN EL NIVEL DE GRAVEDAD Y CONTROL DEL ASMA (PROYECTO IRIS-ASMA)

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of both sexes aged 18-70 years attending outpatient clinics diagnosed with asthma at least one year before. GINA/GEMA criteria will be used to diagnose asthma and to rate its severity. Exclusion Criteria: Illiterate patients; very severe, disabling comorbidity; prior non-inflammatory nasosinusal disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Study Of PF-04449913 Administered Alone In Select Solid Tumors

Study Overview
=================
Brief Summary
-----------------
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select solid tumors.

Official Title
-----------------
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors

Conditions
-----------------
Solid Tumors

Intervention / Treatment
-----------------
* Drug: PF-04449913


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histological or cytological diagnosis of advanced/metastatic solid tumor Adequate Bone Marrow Function Adequate Renal Function Adequate Liver Function Exclusion Criteria: Patients with known symptomatic brain metastases requiring steroids Current active treatment on another clinical trial Major surgery or radiation therapy within 4-weeks of starting study treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: PF-04449913<br>* Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| First cycle dose limiting toxicities (DLTs) |  | 10 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type, incidence, severity (graded by the national cancer institute [NCI] common criteria for Adverse events [CTCAE], timing, seriousness and relatedness of adverse events to PF-04449913 |  | 26 months | 
| Hedgehog biomarker modulation |  | 26 months | 
| Area under the plasma concentration versus time curve (AUC) and peak plasma concentration (Cmax) of PF-04449913 |  | 26 months | 
| QTc interval |  | 26 months | 
| Objective tumor response |  | 26 months | 
| Progression free survival |  | 26 months | 
| Time to progression |  | 26 months | 
| Duration of response |  | 26 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PF-04449913, Hedgehog Inhibitor, Solid tumor, Pharmacokinetics, Safety, Pharmacodynamics
Comparison of 2 Tests to Diagnose Cognitive Dysfunctions in Alcohol Disease

Study Overview
=================
Brief Summary
-----------------
The objective of this study is therefore to compare the results obtained with these two screening tests, using as gold standard the results obtained by the battery of neuropsychological reference tests.

Detailed Description
-----------------
Recently, a new screening test for cognitive disorders was specifically developed for patients with UAS: BEARNI (Brief Evaluation of Alcohol-Related Neuropsychological Impairments). Since the BEARNI is presented as the reference test, the investigators have systematically proposed it to hospitalized patients, in combination with the usual check-up. In practice, at admission, patients were therefore given two screening tests, the MoCA and the BEARNI. In the event of an anomaly in at least one of these tests, a battery of confirmatory neuropsychological tests was performed.

Official Title
-----------------
Comparison of 2 Tests for Screening for Cognitive Disorders (MoCA / BEARNI)

Conditions
-----------------
Alcohol Use Disorder

Intervention / Treatment
-----------------
* Other: MoCA (Montreal Cognitive Assessment) test
* Other: BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with alcoo use desorder Patient cared for in the addictology department of the University Hospital of Nîmes Exclusion Criteria: refusal to use the data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with alcool use desorders<br>Patient cared for in the addictology department of the University Hospital of Nîmes | Other: MoCA (Montreal Cognitive Assessment) test<br>* the MoCA questionnaire is used to assess cognitive disorders<br>Other: BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test<br>* This questionnaire is used to assess cognitive disorders<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensitivity | comparison of the sensitivity of the 2 tests against the gold standard | Day 1 (only 1 time) | 
| specificity | comparison of the specificity of the 2 tests against the gold standard | Day 1 (only 1 time) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MoCA, BEARNI
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia

Study Overview
=================
Brief Summary
-----------------
Heparin induced thrombocytopenia (HIT) is a kind of catastrophic thrombotic complications after the application of heparin. If HIT without treatment, death rate is as high as 30% to 50%. Early diagnosis of HIT and prevention of thrombosis is very important. This study is planned to assess the use of thrombotic biomarkers in patients with HIT, including thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy monitoring . These biomarkers are monitored in 5-14 days post-operation to assess the risk of thrombosis in HIT patients. All patients were followed up for 30 days, and clinical outcomes, including new thrombus and death, were recorded during follow-up.

Official Title
-----------------
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia

Conditions
-----------------
Heparin-Induced Thrombocytopenia, Thrombosis, Biomarkers

Intervention / Treatment
-----------------
* Diagnostic Test: HIT with thrombosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized patients undergoing cardiac surgery. Receiving unfractionated heparin anticoagulation. Exclusion Criteria: history of heparin-induced thrombocytopenia pregnant woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HIT-group<br>The patients with heparin-induced thrombocytopenia. | Diagnostic Test: HIT with thrombosis<br>* Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.<br>|
| HITTs-group<br>The patients with heparin-induced thrombocytopenia with thrombosis. | Diagnostic Test: HIT with thrombosis<br>* Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.<br>|
| Control group<br>The patients without heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thrombotic event | New thrombosis, including deep venous thrombosis,pulmonary embolism,Cerebral infarction,superior mesenteric artery embolism,artery embolism etc. | 30 days | 
| Deaths | All-cause deaths | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heparin-induced thrombocytopenia, Thrombosis, thrombin-antithrombin, d-dimer, Thrombelastograghy
Temperature and Mortality

Study Overview
=================
Brief Summary
-----------------
The investigators evaluated the spatial association between, cardiovascular diseases (CVD) and stroke mortality rate with average ambient temperature (Ta) , and then used this relationship to model future temporal trends in mortality from CVD and stroke till the end of century (2099) using different warming scenarios across the mainland USA.

Detailed Description
-----------------
the investigators used data on mortality rate (per 100,000 individuals) for CVD and stroke (between 2011 and 2013, age>35years) from the publicly available Centers for disease prevention and control (CDC) web site (www.cdc.gov). CVD mortality was defined as the number of deaths per 100,000 personyears due to circulatory causes (International Statistical Classification of Diseases, Tenth Revision, codes I00-I99).Oak Ridge National laboratory was the source of the ambient temperature data (http://www.daac.ornl.gov: files B01, B02 and C07).The investigators obtained data on prevalence of HTN (HTN was defined as systolic blood pressure (BP) of at least 140 mm Hg, self-reported use of antihypertensive treatment, or both) from county health rankings and roadmaps organisation (www.countyhealthrankings.org), which were estimated based on National Health and Nutrition Examination Survey in five two-year waves from 1999-2008 including 26,349 adults aged 30 years and older and from the Behavioral Risk Factor Surveillance System (BRFSS) from 1997-2009 including 1,283,722 adults aged 30 years and older.

Official Title
-----------------
Impact of Increasing Temperature Over the Coming Century on Mortality From CVD and Stroke

Conditions
-----------------
Cardiovascular Diseases

Intervention / Treatment
-----------------
* Other: all the data collection have done by CDC.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. age>35 years Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| spatial association between, cardiovascular diseases (CVD) and stroke mortality rate with average ambient temperature | spatial association between, cardiovascular diseases (CVD) and stroke mortality rate with average ambient temperature | 2011-2013 |
Revisiting Parental Survey for Screening for Obstructive Sleep Apnea in Patients Undergoing Polysomnography

Study Overview
=================
Brief Summary
-----------------
The investigators are proposing a study where the investigators would give a survey to the parents of patients having a sleep study. The survey would contain questions relating to symptoms of sleep apnea and then the investigators would correlate the parent answers to the results of the sleep study.

Conditions
-----------------
Sleep Apnea

Intervention / Treatment
-----------------
* Other: Sleep apnea symptom survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient coming for sleep study at Nationwide Children's Hospital and parent willing to fill out questionnaire. Children ages 3-18 years old regardless of sex or race. Exclusion Criteria: Parental refusal.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sleep study<br>Patients who are having a sleep study done at NCH to diagnose sleep apnea. | Other: Sleep apnea symptom survey<br>* Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep apnea symptoms | Parents or caregivers will be asked to complete a questionnaire regarding possible symptoms related to sleep apnea. | 1 Day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sleep study, NCH